Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.51%
median of 391 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.14B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$1.12B
Gross Margin
77.26%
TTM Avg
80.62%
3Y Avg
79.35%
5Y Avg
80.86%
Market Cap
$1.12B
Gross Margin
47.68%
TTM Avg
50.27%
3Y Avg
51.23%
5Y Avg
48.58%
Market Cap
$1.16B
Gross Margin
88.05%
TTM Avg
93.34%
3Y Avg
92.32%
5Y Avg
92.94%
Market Cap
$1.20B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.05B
Gross Margin
73.53%
TTM Avg
70.13%
3Y Avg
70.04%
5Y Avg
68.74%
Market Cap
$1.24B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$989.05M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
50.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.14B | 0.00% | 0.00% | 0.00% | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | 77.26% | 80.62% | 79.35% | 80.86% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 47.68% | 50.27% | 51.23% | 48.58% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 88.05% | 93.34% | 92.32% | 92.94% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | 0.00% | 0.00% | 0.00% | 0.00% |
| Cronos Group Inc. (CRON)vs › | $1.21B | 36.16% | 31.39% | 23.56% | 1.95% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 73.53% | 70.13% | 70.04% | 68.74% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | 0.00% | 0.00% | 0.00% | 0.00% |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | 100.00% | 100.00% | 50.00% | 50.00% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | 0.00% | 0.00% | 0.00% | 16.67% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
